Endosense, a medical technology company focused on enabling the broad adoption of catheter ablation for the treatment of cardiac rhythm disorders, has launched the TOCCATA clinical study to evaluate the safety of the TactiCath™ system with enrollment gaining momentum.
49985
Endosense launches TOCCATA clinical study
44921
Evotec enters into drug discovery collaboration with Shionogi
122708
Medical therapy lowers stroke risk, better than surgery
81434
Company develops genetic test for scoliosis
134512
New type 2 diabetes pill, Tradjenta, approved
30101
Advaxis receives Research coverage
10922
Ethicon Endo-Surgery assigned patent for methods and devices for applying multiple suture anchors
108236
Abbott licenses biomarkers for use in differentiating aggressive from nonaggressive prostate cancer
122574
Drug companies increasingly use medical science liaisons
6349
First patient treated in the EffiKIR trial
149878
Shikatronics joins in the fight against Breast Cancer
59485
Consortium supports next generation drug discovery
162343
Venous ablation becoming wild west?
74053
Therapy makes strides in cancer care
94638
Microsulis Medical announces first US patient treated with Accu2i percutaneous microwave tissue ablation system
122540
Sorin Group and Orange Business Services launch a remote monitoring solution for patients with implanted cardiac devices in Europe
126233
Astex achieves milestones in drug discovery collaboration